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QUANTIFYING COST OUTCOMES DIFFERENTIATED BY GENDER AND AGE IN
THE TREATMENT OF MIGRAINE HEADACHE USING STEP AND STRATIFIED
CARE
Furiak N, Bansal M
Medical Decision Modeling Inc., Indianapolis, IN, USA
OBJECTIVES:The objective of this studywas to estimate the cost savings of STEP vs.
Stratified (STRAT) migraine headache care differentiated by age and gender.
METHODS: Migraine headaches are a prevalent disorder resulting direct costs of
$2,571 per person per year on average which includes hospital visits and prescrip-
tion drug costs. The indirect costs ofmigraine headaches are estimated to be about
$13 billion a year indirectly affecting theworkplace through an estimated $8 billion
due to missed word days alone. A Monte Carlo microsimulation based upon previ-
ously published non-U.S. models was developed to evaluate the cost-benefit of
stratified care based on MIDAS scores vs. the more commonly applied step care.
Although STEP care delays the initiation of triptan therapywhich is generallymore
costly and potentially habit forming, there may be cost-benefit from evaluating
patient history and disease severity throughMIDAS scores and advancing patients
to more advanced therapies in severe cases. RESULTS: As expected, the greatest
cost differences when adopting STRAT was for MIDAS III women age 40-49 due to
the peak prevalence at this age/gender (STRAT vs. STEP $547 vs. $1,572 per case)
with similar trend found for males of the same age ($515 vs. $1,464). However, the
cost differences for STRAT vs. STEP care for aged 60was significant ($136 vs. $326)
and the difference for patients (age 12-17) was $199. Adoption of STRAT care in
routine clinical practice yields differences of $1,025 and $949 per patient per year
for females and males respectively. Further evidence shows that cost differences
for those ages 60 were $190, and those under age 30 were $199. CONCLUSIONS:
Although the differences for the latter two age strata were smaller, they may have
implications for specialized populations such as Medicare and Medicaid and the
impact they have on plan budgets.
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ECONOMIC EVALUATION OF DEXMEDETOMIDINE FOR SEDATION IN THE
INTENSIVE CARE UNIT
Lachaine J, Beauchemin C
University of Montreal, Montreal, QC, Canada
OBJECTIVES: Dexmedetomidine is an alpha-2 receptor agonist used in continuous
infusion for the sedation of critically ill patients in intensive care unit who are
intubated andmechanically ventilated. Compared tomidazolam in the sedation of
intensive care unit patients, dexmedetomidine showed a decrease in time spent on
ventilator, fewer episodes of delirium and reduced incidence of tachycardia and
hypertension. The aim of this study was to assess the economic impact, in a Ca-
nadian context, of dexmedetomidine for sedation in intensive unit care compare
with midazolam, a GABA agonist. METHODS: This economic evaluation was per-
formed using a cost-consequences analysis, according the perspective of Canadian
Health Care system. The time horizon chosen is an intensive care unit stay with a
maximum length of 30 days. Clinical data were obtained from a prospective ran-
domized, double-blinded trial by Riker and al. comparing dexmedetomidine and
midazolam. Costs considered in this evaluation were those of the medications, of
the mechanical ventilation, of the delirium episodes, and those associated with
adverse events requiring an intervention. All costs were adjusted to 2010 and were
reported in Canadian dollars. RESULTS: The average cost ofmedicationwas higher
with dexmedetomidine ($1,930) than with midazolam ($180), but the average cost
associated with mechanical ventilation and with the management of delirium
were lower with dexmedetomidine ($2,939 and $3,630 respectively) than with
midazolam ($4,448 and $5,149). Overall cost per patient with dexmedetomidine
($8,525) was lower thanwithmidazolam ($9,817). Deterministic sensitivity analysis
confirmed the robustness of this difference. CONCLUSIONS: The results of this
cost-consequences analysis indicated that the use of dexmedetomidine is a favor-
able strategy in terms of clinical consequences and economic impact compare to
midazolam. Compared to midazolam, dexmedetomidine is a less expensive strat-
egy associated with a lower occurrence of delirium and a shorter duration of me-
chanical ventilation.
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QUALITY OF LIFE USING TREATMENTS FOR PARKINSON’S DISEASE: AN
ECONOMIC COMPARISON BETWEEN ROPINIROLE AND LEVODOPA/CARBIDOPA
Patil DS, Shah AJ, Sansgiry S
University of Houston, Houston, TX, USA
OBJECTIVES: Parkinson’s disease(PD) is the second common neuro-degenerative
disease in US older adults. Until recently, Levodopa was the only treatment for PD.
Although, Ropinirole is approved by FDA for PD, there are no cost-effectiveness
studies comparing these treatments. The objective of our study is to perform cost-
effectiveness analysis comparing Ropinirole and the combination therapy of
Levodopa/Carbidopa in the treatment of PD.METHODS: A cost-effectiveness anal-
ysis was performed from the patient’s perspective to compare Ropinirole and
Levodopa/Carbidopa treatment in PD patients using a decision tree model as a
pragmatic tool to derive comparative information on the costs and effectiveness of
these two strategies over a 5-year period. A predictive model was developed to
capture utilization, such asmedication(drug) costs, physician costs, caregiver time,
and productivity loss. Clinical information was derived from a comparative effec-
tiveness study. All direct and indirect costs were obtained from pharmacists, pub-
lished literature, and medical practitioners. Effectiveness was measured in terms
of quality adjusted life years(QALY) reported in literature. Costs were adjusted to
2009 U.S. dollars. One way and two way sensitivity analyses with 25% change in
cost and 20% change in QALY values were performed and incremental cost effec-
tiveness ratio(ICER) was calculated. RESULTS: The Ropinirole therapy resulted in a
gain of 2.82 QALY’s at a cost of $107,062 compared to Levodpo/Carbidopa combi-
nation therapy which resulted in a gain of 2.35 QALY’s at a cost of $102,423 at the
end of 5 years. The expected cost per QALYwas $37,965 for Ropinirole while that of
Levodopa/Carbidopa combination was $43,584. One way and two way analyses
were consistent, validating the results. ICER was found to be $9,870 per QALY for
switching from Ropinirole to Levodopa/Carbidopa therapy. CONCLUSIONS: Our
cost-effectiveness analysis indicates that Ropinirole is a better option as compared
to Levodopa/Carbidopa for treatment of patient suffering from PD.
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ECONOMIC TRENDS ASSOCIATED WITH NATALIZUMAB THERAPY IN A
COMMERCIALY MANAGED MULTIPLE SCLEROSIS POPULATION
Pill M, Gilkin B
Gemini Healthcare, LLC, Westbrook, CT, USA
OBJECTIVES: Identify a population of multiple sclerosis (MS) patients new to treat-
ment with natalizumab. Observe and record healthcare costs before initiation of
natalizumab and up to 3 years after continuing treatment. Compare and quantify
differences in costs based on patterns of natalizumab use.METHODS: Using inte-
grated medical and pharmacy claims data (IMS LifeLink™ Health Plan Claims and
Longitudinal Prescriptions databases), patients were included in the analysis based on
the presence of a diagnosis of MS (ICD-9 code 340.*) during calendar years 2005
through 2008. Economic information related to the treatment of MS was captured
using the Episode Treatment Group™ software. RESULTS: From the database, 76
MS patients that started natalizumab treatment and had 4 full calendar years of
data were observed. These patients were observed for the year prior to start of
natalizumab treatment in 2006, through the end of the 2008 calendar year. Patients
were stratified by continued use of natalizumab during the study period. For all
patients, there were significant increases in annual pharmacy costs ($17,667 to
$40,399) during the year natalizumab treatment was initiated, in addition to out-
patient medical services ($8,383 to $11,744). For patients who continued natali-
zumab for the entire study period, inpatient costs decreased from $2,630 to an
average of $5 per year; emergency room costs in this group also decreased from a
maximum of $537 to $218 annually. For patients who discontinued natalizumab
during the study period, there were increased inpatient costs after discontinuation
($2,630 to $6,701). CONCLUSIONS: Though the study size is small, the cost obser-
vations can enable decision-makers to better understand costs associatedwith the
short and longer-term use of natalizumab for the treatment of MS.
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MEASURING THE IMPACT OF NATALIZUMAB THERAPY ON HEALTH CARE
UTILIZATION IN A COMMERCIALY MANAGED MULTIPLE SCLEROSIS
POPULATION
Pill M, Gilkin B
Gemini Healthcare, LLC, Westbrook, CT, USA
OBJECTIVES: Identify a population of MS patients new to treatment with natali-
zumab. Observe and record healthcare utilization before initiation of natalizumab
and up to 1 year after continuing treatment. Compare and quantify differences in
healthcare utilization for the period prior to natalizumab treatment through the
following calendar year. METHODS: Using integrated medical and pharmacy
claims data (IMS LifeLink™Health Plan Claims and Longitudinal Prescriptions databases),
patients were included in the analysis based on the presence of a diagnosis of MS
(ICD-9 code 340.*) during calendar years 2006 through 2008. Clinical and utilization
information related to the treatment of MS were captured using the Episode Treat-
ment Group™ (ETG™) episode-building software.RESULTS: From the database, 349
MS patients that were both new to natalizumab treatment in 2007 and had 3 full
calendar years of data were observed. In the year of treatment initiation with
natalizumab, therewas an overall increase in the number of prescriptions received
(14.0 to 22.6 per year), aswell outpatientmedical services (16.1 to 25.6) whichwould
be expected with starting a newMS therapy. In addition to these increases, ER and
inpatient utilization were also on the rise prior to initiation of natalizumab, how-
ever, utilization of ER and inpatient services significantly decreased in the follow-
ing calendar year. During this period, there were also significant decreases in the
amount of drugs used for supportive care ofMS including corticosteroids, antispas-
tic agents, and benzodiazepines. CONCLUSIONS: Healthcare costs were at their
highest in the year natalizumab was initiated. Following initiation of natalizumab
therapy, there was a decrease in ER, inpatient and supportive care utilization.
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MEDICO-ECONOMIC EVALUATION OF LACOSAMIDE ADJUNCTIVE THERAPY IN
THE TREATMENT OF PATIENTS WITH REFRACTORY EPILEPSY IN THE UNITED
STATES
Benhaddi H1, Helmers S2
1UCB Group, Brussels, Belgium, 2Emory University School of Medicine, Atlanta, GA, USA
OBJECTIVES: To calculate and compare the incremental cost-utility ratios for stan-
dard antiepileptic drug (AED) therapy with and without adjunctive lacosamide in
patients with uncontrolled partial-onset seizures. METHODS: The model simu-
lated the treatment pathway of a hypothetical cohort of 1000 patients over two
years from the third party payer perspective in theUnited States in 2010. A decision
tree was split into four phases of six months each during which patients can be-
come seizure free, experience a seizure reduction (responder defined as >50%
reduction in seizures), or withdraw due to non-response. The standard therapy
arm included five adjunctive therapies: carbamazepine, lamotrigine, levetirac-
etam, topiramate, and valproate. The likelihood of being in a particular health state
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has been estimated from clinical trials data. The cost of general practitioner visits,
specialist visits, hospitalizations and emergency department visits were included.
Costs and utility values attached to various health states were taken from the
published literature. RESULTS: Lacosamide adjunctive therapy was associated
with 6,730 avoided seizures and a gain of 38 quality adjusted life-years (QALYs),
compared to the standard therapy armwithin the two-year timeframe. Treatment
with lacosamide was associated with a cost of $223 per seizure avoided, and
$39,574 per QALY gained versus standard therapy over two years and falls within
acceptable thresholds of cost-effectiveness in the United States. Results calculated
for 6-, 12- and 18-month follow-up showed respective incremental cost-utility ra-
tios of $55,465, $46,587 and $44,559 and cost per seizure avoided of $733, $305 and
$260. Using a willingness-to-pay threshold of $50,000 per QALY, 77% of the simu-
lations fell below this value after 2 years of treatment. CONCLUSIONS: Lacosamide
was shown to be a cost-effective adjunctive treatment in patients with uncon-
trolled partial-onset epilepsy in the United States.
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THE RELATIONSHIP BETWEEN ALTERNATIVE MEDICATION POSESSION RATIO
THRESHOLDS AND OUTCOMES: EVIDENCE FROM THE USE OF GLATIRAMER
ACETATE
Oleen-Burkey M1, Castelli-Haley J1, Dor A2, Lage M3
1Teva Pharmaceuticals, Kansas City, MO, USA, 2George Washington University, Washington,
DC, USA, 3HealthMetrics Outcomes Research, Groton, CT, USA
OBJECTIVES: Examinehowchanges in themedication possession ratio (MPR) affect
patient outcomes among multiple sclerosis (MS) patients treated with glatiramer
acetate (GA; Copaxone®). METHODS: Data were obtained from i3 InVision Data
Mart for january 1, 2006 – March 31, 2010. Patients were included if they were
diagnosed with MS, initiated therapy with GA, and had continuous insurance cov-
erage from 6 months prior through 24 months post initial use of GA (N839).
Multivariate regressions which controlled for patient characteristics examined the
association between achievement of alternative MPR goals and patient relapses
and charges. Logistic regressions were used to examine the relapses, while gene-
ralized linear models were used to examine charges. RESULTS: Patients who
achieved an MPR of at least 0.7 had significantly lower odds of relapse, with
achievement of a threshold of 0.7, 0.8 or 0.9, respectively, associated with an odds
ratio of relapse of 0.545 (95% CI 0.351 – 0.824), 0.530 (95% CI 0.371 – 0.870), and 0.421
(95% CI 0.260 – 0.679). Larger reductions in total direct medical charges, excluding
drugs, were seenwith higherMPR thresholds, For example, achievement of anMPR
threshold of at least 0.5 was associated with $1524 lower total charges (P0.0034),
while a MPR threshold of 0.90 was associated with $1825 lower charges (P0.0005).
Examining MS-related total charges, exclusive of drugs, revealed that a MPR
threshold of 0.90 was associated with $986 lower total MS-related charges
(P0.0498). Results also found an association between patient adherence to GA and
statistically significant reduction in inpatient, ER, outpatient, MS-related inpatient
and MS-related outpatient charges. CONCLUSIONS: As adherence improves the
odds of relapse decreases and cost-savings, exclusive of drugs, generally increase.
Results suggest that, despite the higher costs associated with increased usage of
GA, patient outcomes are improved and there are cost-offsets associated with
“compliant” use of the medication.
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VALIDATION OF THE HUNTINGTON CLINICAL SELF-REPORTED INSTRUMENT
(H-CSRI), A CLINIMETRIC PATIENT ASSESSED SCALE FOR PATIENTS WITH
HUNTINGTON’S DISEASE
Clay E1, Dorey J2, Toumi M3, Tedroff J4, Squitieri F5, De Nicola N5, Verny C6
1Creativ Research, Paris, France, 2Creativ Ceutical, Paris, France, 3University of Lyon, Lyon,
France, 4NEUROSEARCH, Ballerup, Denmark, 5Neurogenetics and Rare Disease Centre, Pozzi,
Italy, 6Centre national de référence des maladies neurogénétiques, Angers, France
OBJECTIVES:Huntington’s disease (HD) is a rare neurodegenerative disease affect-
ingmotor, cognitive and psychological function. Data collection is difficult because
of the low prevalence and the small number of specialized centers. The creation of
a specific self-administered questionnaire covering various clinical aspects of the
disease would make the HD-patient clinical data collection easier. Such an instru-
ment also offers the advantage of allowing a remote follow-up and getting infor-
mation on the development of motor, functional and behavioral disorders of HD
patients perceived by the patient himself. The objective of this study is to validate
a new self-reported clinical instrument for HD-patients.METHODS: The European
HD burden study (Euro-HDB) is an ongoing cross-sectional survey among HD-pa-
tients and their caregivers in six European countries. The H-CSRI, a self-reported
instrument based on the Unified Huntington’s Disease Rating Scale (UHDRS) and
developedwith the expertise of a neurologist and a psychiatrist, was administered.
It included three subscales assessing themotor, functional and behavioural ability.
Classical test theory and item response theory were used to assess its clinimetric
properties. RESULTS: Among 311 patients from both Italy and France, item re-
sponse rates range from 86% to 99%. There was a floor effect on items related to
psychotic disorder in the behavioral subscale, because these symptoms do not
affect all patients. The H-CSRI showed an acceptable reliability (Cronbach’s al-
phas 0.74). Factor analyses demonstrated a satisfactory construct validity. More-
over, the item internal consistency and item discriminant validity criteria were
met. The differential item functioning analyses showed no item bias between the
two countries and between genders. CONCLUSIONS: These data support the valid-
ity of the H-CSRI to assess the health status for patients with HD. Planned next
steps include assessments of responsiveness to change, test–retest reliability and
convergence between UHDRS and H-CSRI scales.
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QUALITY OF LIFE AMONG PATIENTS SUFFERING FROM MIGRAINE: HEALTH
UTILITY BY FREQUENCY OF HEADACHE DAYS
Gillard P1, Devine B2, Bloudek LM1, Liu L1, Varon SF1, Lipton RB3, Sullivan SD2
1Allergan, Inc., Irvine, CA, USA, 2University of Washington, Seattle, WA, USA, 3Albert Einstein
College of Medicine, Bronx, NY, USA
OBJECTIVES:Migraine in some patients may be progressive, with increasing head-
ache day frequency leading to Chronic Migraine (CM). The relationship between
headache-days per month (HDPM) and health utility, a measure of health-related
quality of life (HRQoL), among patients with migraine has not been examined.
METHODS: The PREEMPT trials studied 1,384 patients with CM treated with
BOTOX® or placebo. The PREEMPT trials included migraine specific measures.
Noo instrument to directly capture health utility, however, was included. There-
fore, a validated mapping algorithm using patient characteristics, the Migraine
Specific Questionnaire v.2 (MSQ), and the EuroQol-5D (EQ-5D, UK weighted) was
applied to the PREEMPT dataset in order to estimate mean health utility by
health state, defined as 0-3, 4-9, 10-14, 15-19, 20-23, or24 HDPM. Analyses were
performed both regardless of treatment and stratified by treatment arm. Health
utility is a standard scale to measure HRQoL, ranging from 1, representing per-
fect health, to 0, representing death. RESULTS: PREEMPT patients were predom-
inantly female (86%) and Caucasian (90%), with amean age of 41. At week 24, mean
health utility for each of the HDPM categorieswas 0.75 (0-3 HDPM), 0.68 (4-9 HDPM),
0.62 (10-14 HDPM), 0.53 (15-19 HDPM), 0.53 (20-23 HDPM), and 0.52 (24 HDPM). A
similar trend of decreasing utility with increasing HDPMwas observed at baseline,
week 12, and week 56 and when stratified by treatment arm. CONCLUSIONS: An
inverse relationship is seen between health utility and HDPM, with the headache
frequency categories comprising CM (15-19, 20-23, and 24HDPM) associated with
the lowest HRQoL. Health utility defined by HDPM categories will be valuable for
estimating HRQoL gains as a result ofmigraine treatmentswhich aim to reduce the
number of HDPM among those suffering from migraine.
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HEADACHE DAY HEALTH STATES AND TRANSITION PROBABILITIES FOR
PATIENTS WITH CHRONIC MIGRAINE WITH AND WITHOUT HEADACHE
PROPHYLAXIS
Bloudek LM1, Hansen RN2, Liu L1, Batty AJ3, Varon SF1, Lipton RB4, Sullivan SD2
1Allergan, Inc., Irvine, CA, USA, 2University of Washington, Seattle, WA, USA, 3BresMed Health
Solutions, Sheffield, UK, 4Albert Einstein College of Medicine, Bronx, NY, USA
OBJECTIVES: Chronic migraine is an undertreated and debilitating disease associ-
ated with significant morbidity. This research seeks to define meaningful health
states based on published literature and where necessary, expert opinion. Health
states defined by the number of headache-days per month (28 days; HDPM) expe-
rienced by patients with chronic migraine (15 headache days per month) can be
used to calculate transition probabilities that may be applied to cost-effectiveness
modeling. METHODS: Published literature, headache treatment guidelines,
heath utility, and health resource utilization, as well as the baseline distribution
of HDPM in the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Ther-
apy (PREEMPT) clinical trial program were considered to ascertain relevant HDPM
to define migraine health states. Subsequently, pooled trial data were used to
estimate transitions between health states per 12-week treatment cycle for pa-
tients treated with BOTOX® or placebo. Up to 24 weeks of double-blind data is
available from the PREEMPT phase 3 trials, with an additional 32 weeks of open-
label data for BOTOX® treated patients. All available data from the PREEMPT trials
were used to model transitions. A Bayesian approach with a Dirichlet distribution
was used to perform sensitivity analyses of these health state transitions.
RESULTS: We specified 6 unique health states, defined by number of HDPM: 0-3,
4-9, 10-14, 15-19, 20-23, and 24. The pooled trial cohort of 1384 patients (857 with
prior prophylaxis failure) were examined at baseline, week 12 and week 24 to
produce transition probabilities for both all patients and those with prior prophy-
lactic failure. Estimated transition probabilities modeled to one year time horizon
produce distributions that closely replicate the 56-week distribution of the PRE-
EMPT trial population. CONCLUSIONS: This research generated unique migraine
health states to form the foundation of cost-effectiveness models evaluating mi-
graine therapies.
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HEALTH RESOURCE UTILIZATION AND COSTS FOR MIGRANEURS IN SCOTLAND
Bloudek LM1, Hansen RN2, Liu L1, Batty AJ3, Varon SF1, Lipton RB4, Sullivan SD2
1Allergan, Inc., Irvine, CA, USA, 2University of Washington, Seattle, WA, USA, 3BresMed Health
Solutions, Sheffield, UK, 4Albert Einstein College of Medicine, Bronx, NY, USA
OBJECTIVES: Migraine is a debilitating disease with significant morbidity. This
research estimates the health resource utilization and associated cost of adult
Scottish migraneurs within 6 distinct health states, defined by number of head-
ache-days per month (28 days; HDPM), ranging from zero to 28, to inform a cost-
effectiveness analysis of prophylaxis of headache in patients with chronic mi-
graine (15 HDPM). METHODS: Standard cost of illness methods were used to
combine unit costs for physician office visits, inpatient and emergency room en-
counters for migraine, and triptan medication use. Resource utilization data was
taken from the International Burden of Migraine Study. Costs were derived from
the NHS 2008/09 reference costs for England, and from the Personal Social Services
Research Unit (PSSRU) costs. Total costs for each health state were estimated over
a three month time interval. RESULTS: Resource utilization increased across all
categories as the number of HDPM increased. Costs per 3 months ranged from
£35.05 for the 0-3 headache-days health state to £226.14 for the 15 HDPM
health state. The largest cost driver among the 15 HDPM was hospitalization
for migraine, which accounted for 52% of costs in 15 HDPM health state.
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